Samsung Bioepis Receives Positive CHMP Opinion for AYBINTIO® (Bevacizumab)
June 26, 2020 07:12 ET
|
Samsung Bioepis
AYBINTIO®, a biosimilar candidate referencing Avastin®i (bevacizumab), is Samsung Bioepis’ second oncology biosimilar to be recommended for marketing authorization by the European Medicines...